Company ProfilePremium

Alphanco Venture Corp

Company Profile Analysis

Ticker: MRVL.TO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alphanco Venture Corp - Company showcase

Year Founded & Workforce

2019

Alphanco Venture Corp logo

Alphanco Venture Corp Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alphanco Venture Corp Overview

Marvel Biosciences is a Calgary-based, preclinical-stage pharmaceutical developer. It pursues a "drug redevelopment" strategy: it makes patentable synthetic derivatives of drugs that are already approved and off-patent, to target new diseases with less chemistry and safety risk than de novo discovery. Its only clinical-path asset is MB-204, a fluorinated analogue of istradefylline. Istradefylline is the adenosine A2A receptor antagonist approved for Parkinson's disease, and the only approved drug in that class. Marvel positions MB-204 for socio-behavioural symptoms in neurodevelopmental disorders: Rett syndrome, Fragile X syndrome and autism spectrum disorder, with depression as a further indication. Preclinical data show the compound outperforming trofinetide, the only approved Rett therapy, in mouse models. MB-204 has completed cGMP synthesis and 4-week GLP toxicology. The company has composition-of-matter patents granted or allowed in the US, China, Japan and Australia, and it is preparing a first-in-human trial in Australia with Novotech. Marvel has no revenue and a balance sheet with negative equity, so it depends on frequent small equity raises and non-dilutive grants.


Company's own description. In its 2026 press releases, Marvel describes itself and Marvel Biotechnology Inc. as a Calgary-based, preclinical-stage pharmaceutical development company using a drug-redevelopment approach. It also describes itself as a drug-discovery company developing new therapeutics for autism spectrum disorder and related conditions (Newsfile, 20 May 2026 and 29 Sep 2026; Stockwatch, 30 Mar 2026). Its releases explain that A2A blockade has a growing evidence base in neurological diseases beyond Parkinson's, including autism, depression and Alzheimer's disease (Newsfile, 29 Sep 2026).

Business model. Marvel is a single-asset development company. It owns intellectual property and outsources almost all activity:

Discovery and chemistry: designs new chemical entities derived from approved drugs (fluorination of istradefylline in MB-204's case).

Preclinical pharmacology: commissions efficacy studies in animal models of depression, Rett syndrome, Fragile X and autism.

CMC and toxicology: cGMP synthesis and 4-week GLP toxicology are complete (Investing News Network, Novotech release, 2026).

Clinical development: to be run by CRO Novotech in Australia, using Australia's R&D tax incentive (company cites over 40%) and the Clinical Trial Notification (CTN) scheme.

Monetisation: management has said it would prefer to partner MB-204 with a single pharmaceutical licensee rather than license indication by indication (Crux Investor interview).

Revenue model. Marvel has no product, service, subscription or licensing revenue. Every fiscal year from FY2020 to FY2025, and the trailing period to 30 Apr 2026, shows nil revenue (Weiss Ratings; TipRanks; Simply Wall St). The expected future model is licensing or partnering (upfront, milestones, royalties) or an outright sale of the asset. No such agreement has been disclosed.

Value chain position. Marvel sits at the earliest value-creating stage: IP generation plus preclinical and early clinical de-risking. It aims to exit before the expensive Phase II/III and commercial stages.

Target patients and end-markets. Rett syndrome (rare, mostly female, MECP2 mutations); Fragile X syndrome (the most common inherited cause of intellectual disability); autism spectrum disorder (socio-behavioural symptoms); depression and anxiety; Alzheimer's disease. Earlier corporate descriptions also list ADHD, NASH-associated liver fibrosis and immuno-oncology (A2A in cancer), but these are no longer the focus (moomoo profile; Yahoo Finance profile).

Independent characterisation. Marvel is a nano-cap "option on one molecule." The scientific rationale is credible. Istradefylline has human safety data, and A2A antagonism has peer-reviewed support in neuropsychiatric models. The company's choices are capital-efficient: an Australian Phase I, grant funding, and a contract CFO. However, the balance sheet is very weak. At 30 Apr 2026, current assets were about C$345K against well over C$1.8M of current liabilities. Each financing has been small: C$1.02M in May 2025 and C$1.60M in September 2026, the latter against a C$3.0M target. Value depends on (a) starting and completing Phase I, (b) using the rare-disease regulatory route (Orphan Drug Designation, possibly Rare Pediatric Disease designation) and (c) attracting a partner before dilution erodes shareholder value.

Strategy

Stated strategy (company themes, paraphrased):

  1. Drug redevelopment: create patentable derivatives of approved drugs to lower development risk, cost and time.

  2. Focus on neurodevelopmental rare diseases first: Rett syndrome and Fragile X, where orphan incentives and high unmet need support faster regulatory paths, then broaden to autism spectrum disorder and depression.

  3. Capital-efficient clinical execution: Phase I in Australia for regulatory speed and tax-credit recovery.

  4. Non-dilutive funding: NRC IRAP, Alberta Innovates AICE, and strategic co-funding from 5 Horizons.

  5. Extend IP life: formulation patents (pediatric liquid) on top of composition-of-matter patents.

  6. Partnering exit: prefer a single global partner for MB-204 (Crux Investor interview).

Medium-term targets / guidance. No financial targets have been issued. Operational guidance has been to start Phase I in Australia: first "Q2 2026" (5 Horizons release), and in an earlier interview "within 6–12 months" (Crux Investor). After Phase I, the company aims to go directly into Phase II/III studies in rare diseases. ESG and sustainability commitments have not been disclosed. There is no formal cost programme, but cost discipline is evident from the shrinking loss.

Products & Services

Marvel has no marketed products. The catalogue below lists its development assets.

MB-204 (lead asset)

AttributeDetailSource
DescriptionA new fluorinated derivative of istradefylline (an approved anti-Parkinson's adenosine A2A antagonist)Newsfile, 29 Sep 2026
MechanismSelective adenosine A2A receptor antagonism; neuroactiveNovotech CRO release, 2026
Claimed differentiationBetter pharmacokinetics than the parent compound; new composition-of-matter IPStockTitan, Jun 2026
Development stagePreclinical, Phase I-ready. cGMP synthesis and 4-week GLP toxicology complete. Phase I (healthy volunteers: safety, tolerability, PK) planned in Australia with NovotechINN; BioSpace (5 Horizons)
Phase I timingOriginally expected to start in Q2 2026 (5 Horizons release, Apr 2026). As of Sep 2026 the company was raising money for a Phase I deposit, so first dosing had not been announcedBioSpace; Newsfile, 29 Sep 2026
IndicationsRett syndrome; Fragile X syndrome; autism spectrum disorder (socio-behavioural symptoms); depression; anxiety; Alzheimer's diseaseCompany releases
Key preclinical dataRett: beat trofinetide across several behavioural endpoints, including after drug cessation. Fragile X: reversed behavioural and cognitive deficits in mice. Depression: rapid reversal of depressive behaviour in models (an interview cites about 90% reversal within an hour; company characterisation, not peer-reviewed)StockAnalysis feed; Crux Investor
FormulationsStandard liquid formulation used in preclinical work. Two pediatric small-volume oral liquid formulations identified (Apr 2026) for oral syringe or feeding-tube dosing. New formulation patents filedGlobeNewswire, 16 Apr 2026
Target customerPediatric and adolescent patients with neurodevelopmental disorders; adults with depression; future pharma licenseeCompany releases
Regulatory plansFDA Orphan Drug Designation (Rett) planned; after Phase I, the company aims to move quickly into Phase II/III in rare-disease indicationsBioSpace; moreblossom
PricingNot applicable (pre-commercial)—

Earlier-stage and historical pipeline

ProgrammeDescriptionStatusSource
Other A2A antagonist derivativesFurther NCEs derived from off-patent drugs that inhibit the A2A receptorDiscovery; not prioritisedmoomoo profile; roic.ai
Oncology (A2A in tumour immunology)A2A inhibitors for cancerHistorical / deprioritisedroic.ai profile
NASH-associated liver fibrosisNon-neurological use of MB-204 / A2A antagonismHistorical preclinical claimYahoo Finance profile
ADHD, Alzheimer'sNeurological indications in earlier corporate descriptionsPreclinical claimsmoomoo; roic.ai
Non-hallucinogenic neuroplasticity programmeListed in aggregator descriptionsDetails not publicly disclosedYahoo Finance; Simply Wall St
Undisclosed targetsCompany said it was exploring further undisclosed targets—moomoo profile

Financial Narrative

Income statement

Sources: FY2021–FY2023 from TipRanks. FY2024 net income from TipRanks (rescaled) and roic.ai; FY2024 EPS from roic.ai. FY2025 from Weiss Ratings TTM at 31 Jul 2025. FY2025 weighted shares from roic.ai (rounded).

EPS discrepancies: roic.ai shows FY2021 at -0.17 against TipRanks -0.09, and FY2025 at -0.05 against Weiss -0.03. Weiss's TTM "average basic shares" of 174–228M is an aggregation error (it sums quarterly averages) and should be ignored.

FY2020 (Marvel Biotechnology Inc. predecessor): net loss C$955.66K; weighted shares 7.37M; EPS -0.13 (TipRanks).

Operating loss and EBITDA

Sources: TipRanks for FY2021–FY2024 EBITDA and FY2022–FY2024 operating loss; Weiss TTM for FY2025. FY2021 operating income appears in TipRanks as +806K, which is probably a classification artefact of RTO accounting, so it is excluded. FY2025 EBITDA is not reported by the aggregators.

Margins. Gross, operating, EBITDA and net margins are not meaningful because revenue is nil.

Revenue CAGR. Not meaningful (nil revenue).

Commentary. The loss has narrowed every year since the QT: from C$3.04M in FY2021 to about C$1.59M in FY2025, a fall of 48%. This reflects (a) one-off RTO and listing costs falling out after FY2021, (b) the end of expensive preclinical work (toxicology and cGMP synthesis) by FY2024–FY2025, and (c) tight cost control. FY2025 SG&A of about C$675K was more than 60% of operating expense, which signals very limited R&D spending in that year. The narrowing loss is a sign of constrained funding, not of operating leverage. The loss is expected to widen sharply once Phase I begins.

Recent quarters — FY2025 Q3 to FY2026 Q3

Source: Weiss Ratings quarterly statements (MBCOF).

The Q4 FY2025 loss of C$866K included about C$518K of non-cash items, consistent with year-end share-based compensation or debt and derivative adjustments. Q3 FY2026 reported positive net income of C$319K, alongside C$250K of negative non-cash items and a fall of about C$1.14M in current debt. This points to a gain on debt settlement, extinguishment or revaluation rather than operating income; the MD&A would be needed to confirm. The positive operating cash flow in Q3 FY2026 (C$120K) probably reflects grant receipts or working-capital timing.

Balance sheet

Source: roic.ai (rounded). FY2021 equity was about +C$2M (roic.ai), immediately after the QT.

FY2025 year-end detail (31 Jul 2025, Weiss): cash C$93.1K; total assets C$236.1K; accounts payable C$1.08M; accrued liabilities C$377.7K; current loans/debt C$1.67M. Derived net debt is about C$1.58M.

Goodwill and intangibles: nil on the balance sheet. Patents are expensed, not capitalised. Long-term debt: roic.ai shows about C$1M (FY2023) and C$2M (FY2024), reclassified to current by FY2025. The short-term versus long-term split for other years is not publicly disclosed.

Latest balance sheet (30 Apr 2026): cash C$317.8K; total assets C$344.8K; payables plus accruals about C$1.32M; current debt C$564.2K. Seeking Alpha reports total liabilities of about US$3.09M at 31 Oct 2025.

Cash flow

Source: Weiss Ratings TTM to 31 Jul 2025.

roic.ai free cash flow per share (C$, rounded), by roic year label: 2021 -0.08; 2022 -0.07; 2023 -0.03; 2024 -0.03; 2025 -0.02.

TTM to 30 Apr 2026: operating cash flow C$-569.1K; equity issued C$851.9K (Weiss).

Ratios

Interpretation. Marvel has been technically insolvent on a balance-sheet basis, with negative equity, since at least FY2023. It survives through repeated small placements, accrued payables that are effectively vendor financing, loans, and director fees paid in DSUs. The September 2026 placement (gross C$1.60M; about C$1.52M after cash finder fees of C$77K) is roughly two years of FY2025-level burn, but only before Phase I spending begins. The disclosed use of proceeds is a Phase I deposit, which implies the full trial cost is not yet funded.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (As Reported) Overview

Segment (as reported)ContentsProducts / programmesSegment operating result

Single segment: drug development (Canada)

Marvel Biosciences Corp. (parent, listed) and Marvel Biotechnology Inc. (100% subsidiary, IP and R&D)

MB-204 and earlier-stage A2A antagonist derivatives

Equals consolidated operating loss

Segment Revenue

SegmentFY2023FY2024FY2025

Drug development revenue (CAD K)

000

Group Entities

EntityRoleOwnership

Marvel Biosciences Corp.

TSXV-listed parent; formerly Alphanco Venture Corp.

Public

Marvel Biotechnology Inc.

Operating and IP-holding subsidiary

100%

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CAD K)

00000

Gross profit (CAD K)

00000

Pre-tax income (CAD K)

-3,040-2,550-2,290-1,650-1,590

Net income (CAD K)

-3,040-2,550-2,290-1,650-1,590

Basic EPS (CAD)

-0.09-0.08-0.06-0.04-0.03

Diluted EPS (CAD)

-0.09-0.08-0.06-0.04-0.03

Dividends per share (CAD)

00000

Weighted avg basic shares (M)

32.5932.7639.6639.9647

Key Financials

MetricFY2022FY2023FY2024FY2025

Operating income (CAD K)

-2,540-2,320-1,220-1,070

SG&A (CAD K)

———675

Income Statement

MetricFY2021FY2022FY2023FY2024

EBITDA (CAD K)

-1,250-2,510-2,250-1,540

Balance Sheet

MetricQ3FY25 (Apr-25)Q4FY25 (Jul-25)Q1FY26 (Oct-25)Q2FY26 (Jan-26)Q3FY26 (Apr-26)

Total operating expenses (CAD K)

176.1355.7182.2189.3248.5

SG&A (CAD K)

175.8173.3140.8185.4195.8

Net income (CAD K)

-181.1-866.3-246.6-217.9319.2

Cash from operations (CAD K)

-373.8-240.3-128.6-320.2120.0

Equity issued (CAD K)

925.093.8683.175.00

Cash and ST investments (CAD K)

281.593.1452.1202.1317.8

Total assets (CAD K)

362.2236.1487.4235.6344.8

Accounts payable (CAD K)

1,0101,0801,1501,0601,080

Accrued liabilities (CAD K)

234.4377.7297.6315.0239.0

Current debt / loans (CAD K)

723.71,6701,6501,700564.2

Liquidity & Coverage Ratios and Per-Share Data

MetricFY2023FY2024FY2025

Total equity (CAD Mn)

-2-3-4

Working capital (CAD Mn)

-1-3-4

Book value per share (CAD)

-0.05-0.08-0.09

Cash Flow

MetricFY2025

Operating cash flow (CAD K)

-824.9

Capex (CAD K)

0

Free cash flow (CAD K)

-824.9

Equity issuance (CAD K)

1,020

Financing cash flow (CAD K)

658.3

Dividends paid (CAD K)

0

Buybacks (CAD K)

0

Net change in cash (CAD K)

-166.5

Financial Analysis

RatioValueBasis

ROE

Not meaningful (negative equity)

—

ROA

Roughly -670% (FY2025 net loss / year-end assets; derived, illustrative only)

Weiss data

Current ratio

About 0.08 (31 Jul 2025); about 0.18 (30 Apr 2026)

Derived from Weiss current assets / identified current liabilities

Debt / equity

Not meaningful (negative equity)

—

Net debt / EBITDA

Not meaningful (negative EBITDA)

—

Interest coverage

Not meaningful (negative EBIT)

—

Asset turnover

0 (nil revenue)

—

Geographic Revenue

RegionFY2023FY2024FY2025

Canada revenue (CAD K)

000

Australia revenue (CAD K)

000

United States revenue (CAD K)

000

Valuation Snapshot

MetricValueSource

Recent share price (TSXV)

About C$0.16

Investing.com; roic.ai

52-week range

C$0.13–0.32

Investing.com

Recent placement price

C$0.15 (Sep 2026)

Newsfile

Market cap

About C$10.1–10.4M (pre-placement); about C$11.8M (post-placement, derived)

roic.ai; Investing.com

Enterprise value

About US$7.05M (Jan 2026, Yahoo, MBCOF)

Yahoo Finance

OTC (MBCOF) price

About US$0.10–0.11

Yahoo; Weiss

P/E

n/m (losses)

—

EV/EBITDA

n/m

—

EV/Sales

n/m

—

P/B

n/m (negative book value)

—

Analyst consensus

None; no sell-side coverage and no EPS estimates

Wealth Awesome, Jun 2026

Dividend history / policy

Never paid; none expected

Aggregators

Credit ratings (Moody's / S&P / Fitch)

Not rated

—

Debt maturity profile

Loans and debt classed as current (C$564K at 30 Apr 2026); detailed schedule not publicly disclosed

Weiss

Share Count (M)

MetricFY2021FY2022FY2023FY2024FY2025

Weighted avg basic shares (M)

32.5932.7639.6639.9647

Analyst Conclusions

Management guidance. The company plans to start a healthy-volunteer Phase I of MB-204 in Australia with Novotech, funded by the September 2026 placement (deposit), Alberta Innovates AICE, 5 Horizons co-funding and the Australian R&D tax incentive. It intends to seek FDA Orphan Drug Designation in Rett and then move into Phase II/III in rare diseases. No financial guidance has been given and there is no consensus forecast.

Bull case:

  1. Mechanism plus IP. A derivative of an approved, human-validated A2A antagonist with composition-of-matter protection in the US, China, Japan and Australia offers an unusually de-risked starting point for a nano-cap.

  2. Rare-disease economics. Daybue's revenue (about US$348M in FY2024) proves Rett patients and payers will fund therapy. Positive Phase I data plus Orphan Drug Designation could re-rate a company valued at about C$12M.

  3. Cheap trial and validation. Australian tax credits and three outside funders lower the net Phase I cost and lend credibility.

Bear case:

  1. Solvency. Negative equity of about -C$4M, payables of about C$1.1M and a raise only half filled show investor demand is constrained. Funding the full Phase I is likely to need further placements below or near C$0.15.

  2. Translational risk. All efficacy evidence comes from company-reported mouse studies. ASD and Fragile X have a long record of trial failures.

  3. Competitive and timeline risk. Phase I has already slipped beyond Q2 2026. Gene therapies and late-stage Fragile X assets may set the standard of care before MB-204 reaches efficacy trials.

Analyst verdict. Alphanco Venture Corp. is no longer a company in its own right. It was the TSXV capital pool shell that became Marvel Biosciences Corp. in mid-2021, and anyone holding the "AVC.P / Australia" record should update it to TSXV: MRVL / OTCQB: MBCOF, Calgary, Canada. Marvel is a tightly run but financially fragile single-asset biotech. Its scientific idea is coherent: take the only approved adenosine A2A antagonist, fluorinate it for better pharmacokinetics and new patents, and aim it at socio-behavioural symptoms in rare neurodevelopmental disorders, where approved options are scarce and orphan incentives are strong. Execution has been solid on a small budget. In 2026 alone the company completed cGMP/GLP readiness, built a four-jurisdiction composition-of-matter estate, selected a CRO, identified pediatric formulations and secured three non-dilutive or strategic funders. Annual losses fell by nearly half from FY2021 to FY2025.

The financial position, however, overrides the science in the near term. Equity is negative, working capital is deeply negative, and suppliers are carrying more than C$1M of payables. The latest placement raised only C$1.6M of a C$3.0M target, after two deadline extensions, and was explicitly sized for a Phase I deposit. Investors should therefore expect further dilution before any human data arrive. The share count has already nearly doubled since FY2024. The Phase I start has slipped past guidance, and every efficacy claim so far comes from mouse studies reported by the company.

On balance, MRVL is a speculative, binary, venture-style exposure. The decisive monitorables are the FY2026 going-concern disclosure, confirmation that the first subject has been dosed in Australia, and any Orphan Drug Designation progress. A partnership with an A2A-experienced or Rett-focused company (Kyowa Kirin, Acadia or similar) would transform the risk profile. Without one, the base case is incremental, dilutive progress, with value depending on Phase I safety and PK data expected in 2027 at the earliest.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation (latest available)Source

J. Roderick (Rod) Matheson

Executive Chairman and CEO

CEO since Jul 2021 (about 5.2 yrs)

Was CEO of Marvel Biotechnology before the QT; owns about 11.2% of shares

C$150K total, all salary (Simply Wall St). Yahoo shows C$109.6K. Sources conflict

Simply Wall St; Yahoo Finance

Dr. Mark Williams, PhD, MBA

President, Chief Science Officer and Director

Since at least 2021

Scientific lead; born 1972

C$109.6K (Yahoo)

Yahoo Finance; Newsfile

Harpreet (Harry) Nijjar, CPA, CMA

Chief Financial Officer

Since 1 Feb 2022

Managing Director at Malaspina Consultants (contract CFO services, joined 2011); born 1988

C$84K (Simply Wall St) vs C$60.3K (Yahoo). Sources conflict

Newsfile, 1 Feb 2022; Yahoo; Simply Wall St

Jacqueline Groot

Corporate Secretary

———

Yahoo; moomoo

Preston Maddin

Former CFO

Until 31 Jan 2022

——

Newsfile, 1 Feb 2022

“—” = not publicly disclosed.

Board of Directors

DirectorRoleIndependentBackgroundSource

J. Roderick Matheson

Chair

No (executive)

CEO

Newsfile AGM release

Dr. Mark Williams

Director

No (executive)

President and CSO

moomoo

Neil A. Johnson

Lead Independent Director

Yes

—

moomoo

S. Randall Smallbone

Director

Yes

Former CFO of three public companies (Migao, KCP Income Fund, Decoma International/Magna); chairs Burlington Economic Development Corp. and Joseph Brant Hospital boards

Newsfile AGM release

Babak Pedram

Director (since 23 Nov 2022)

Yes

More than 15 years in investment banking and capital-markets advisory; founder and president of Virtus Advisory Group (the company's former IR firm); BSc and MSc, Queen's University

Newsfile, 24 Nov 2022

Jeremy Fehr

Director (elected 2022)

——

Newsfile AGM release; moomoo

“—” = not publicly disclosed.

Major Shareholders

HolderStakeSource

J. Roderick Matheson (CEO)

About 11.2%

Simply Wall St

Institutional holders (top 10)

Not publicly disclosed; institutional ownership is believed to be negligible for a TSXV nano-cap

—

5 Horizons Ventures

Strategic funding partner (15% of Phase I CRO costs); any equity stake not disclosed

BioSpace, Apr 2026

Competitive Landscape

Competitors by Segment

AreaCompetitorAsset / approachStageApprox. scaleRelative positioning against Marvel

Rett syndrome

Acadia Pharmaceuticals (NASDAQ: ACAD)

Trofinetide (Daybue), the only FDA-approved Rett therapy

Marketed

FY2024 revenue about US$958M (Daybue about US$348M)

Incumbent; MB-204 claims better preclinical efficacy

Rett syndrome

Neurogene (NASDAQ: NGNE)

NGN-401 gene therapy

Clinical

Pre-revenue

Disease-modifying approach

Rett syndrome

Taysha Gene Therapies (NASDAQ: TSHA)

TSHA-102 gene therapy

Clinical

Pre-revenue

Disease-modifying approach

Rett / CNS

Anavex Life Sciences (NASDAQ: AVXL)

Blarcamesine (sigma-1)

Clinical

Pre-revenue

Small-molecule competitor

Fragile X

Harmony Biosciences (NASDAQ: HRMY; acquired Zynerba)

Zygel (cannabidiol gel)

Late clinical

FY2024 revenue about US$715M

Late-stage rival

Fragile X

Shionogi / Tetra Therapeutics

Zatolmilast (PDE4D inhibitor)

Late clinical

Shionogi is a large pharma

Late-stage rival

A2A antagonism (Parkinson's)

Kyowa Kirin (TSE: 4151)

Istradefylline (Nourianz/Nouriast), the parent molecule

Marketed

Group revenue about ¥0.5 trillion

Validates the mechanism; possible partner or competitor

A2A antagonism (oncology)

Arcus Biosciences (NYSE: RCUS); Corvus (NASDAQ: CRVS)

Etrumadenant; ciforadenant

Clinical

Collaboration revenue (Arcus)

Same target, different therapeutic area

Autism (socio-behavioural)

Various: oxytocin and vasopressin-pathway programmes, bumetanide programmes (several failed)

Various

Clinical / failed

—

Field with many failures; high bar

Depression

J&J (Spravato), Sage/Biogen (zuranolone) and others

Various

Marketed

Very large

Crowded; MB-204's depression positioning is secondary

Peer Comparison FY2025

MetricMarvel BiosciencesAcadiaNeurogeneTaysha

Latest FY revenue

C$0 (FY2025)

About US$958M (FY2024)

Pre-revenue

Pre-revenue

Revenue growth

—

Positive (Daybue launch)

——

Operating margin

n/m

Positive (FY2024)

n/m

n/m

R&D intensity

About C$0.4M absolute (FY2025 proxy)

Significant (hundreds of US$M)

Tens of US$M

Tens of US$M

Stage of lead Rett asset

Preclinical (Phase I pending)

Approved

Phase 1/2

Phase 1/2

Recent Developments

The Phase I timing has, however, slipped beyond the Q2 2026 guidance.

Company Snapshot

2019

Founded

Calgary, Canada

Headquarters

SWOT Analysis

Strengths

  • Validated mechanism: MB-204 is derived from istradefylline, the only clinically approved A2A antagonist (Newsfile, 29 Sep 2026).
  • Global composition-of-matter IP: US 12,570,656 B2, plus grants in China and Japan and an accepted application in Australia (2026 releases).
  • Phase I-ready package: cGMP synthesis and 4-week GLP toxicology are complete (Novotech release, 2026).
  • Differentiated preclinical data: beat trofinetide in Rett models, including after the drug was stopped (2025 data release).
  • Non-dilutive validation: NRC IRAP (Feb 2026), Alberta Innovates AICE (Mar 2026) and 5 Horizons co-funding (Apr 2026).
  • Lean cost base: net loss cut from C$3.04M (FY2021) to C$1.59M (FY2025).
  • Management alignment: the CEO owns about 11.2% (Simply Wall St).

Weaknesses

  • Negative equity: about -C$4M at FY2025 (roic.ai).
  • Very little cash: C$93.1K at 31 Jul 2025 and C$317.8K at 30 Apr 2026 (Weiss).
  • Heavy payables: about C$1.08M of accounts payable for five straight quarters (Weiss), implying stretched suppliers.
  • Under-subscribed financing: C$1.60M raised against a C$3.0M target, after two deadline extensions (Newsfile, Sep 2026).
  • Single asset: all value rests on MB-204.
  • No human data, and Phase I guidance has slipped (Q2 2026 guidance was missed).
  • Thin internal team: contract CFO; employee count not disclosed.

Opportunities

  • Orphan Drug Designation filing for Rett (planned).
  • Fragile X data (2026) opens a second orphan indication.
  • Australian R&D tax incentive of over 40% lowers net Phase I cost.
  • Pediatric formulation patents could extend exclusivity.
  • Partnering: management prefers a single global partner; Kyowa Kirin, Acadia or Harmony are logical strategic counterparties (analyst inference, not disclosed by the company).
  • Warrant exercise: 10.65M warrants at C$0.20 could add about C$2.1M if the share price rises above C$0.20 (derived).

Threats

  • Dilution: shares rose from about 40M (FY2024) to about 73.7M (Oct 2026) (TipRanks; Stockwatch; Newsfile).
  • Gene-therapy competition in Rett (Neurogene, Taysha).
  • Late-stage Fragile X competitors (zatolmilast; Zygel).
  • Translational risk: many ASD and Fragile X failures in the clinic.
  • Going-concern risk from negative working capital.
  • Liquidity: OTC volume is around 13.7K shares a day (Yahoo), and the TSXV nano-cap market is thin.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2 May 2025Update on placement announced 28 Mar 2025 Newsfile company pageFinancing progress
12 May 2025Placement closes, about C$1.02M Simply Wall StRunway extension
2025Second of two final Rett data sets: MB-204 beats trofinetide after drug cessation StockAnalysis feedDifferentiation on durability
2025Plan to seek FDA Orphan Drug Designation for Rett announced StockAnalysis feedRegulatory route
31 Jul 2025FY2025 year-end: net loss about C$1.59M; cash C$93.1K WeissLow liquidity
31 Oct 2025Q1 FY2026: cash rises to C$452.1K after C$683K equity issuance WeissLiquidity rebuild
Late 2025 / 2026Chinese MB-204 patent granted Newsfile company pageIP breadth
31 Jan 2026Q2 FY2026: net loss C$217.9K; cash C$202.1K WeissBurn continues
18 Feb 2026NRC IRAP funding for pediatric liquid formulation NewsfileNon-dilutive capital; IP extension
2026Japanese composition-of-matter patent granted StockTitanIP breadth
2026US notice of allowance, then US 12,570,656 B2 Newsfile company pageMost important market protected
Mar 2026Novotech selected as Phase I CRO INNLast operational step before trial start
30 Mar 2026Alberta Innovates AICE funding for Phase I StockwatchNon-dilutive capital
7 Apr 20265 Horizons Ventures co-funding (15% of CRO costs); Phase I guided to Q2 2026 BioSpaceThird-party validation
16 Apr 2026Two pediatric liquid formulations identified GlobeNewswireFormulation milestone
17 Apr 2026About C$0.5M funding transaction closed Simply Wall StLiquidity
30 Apr 2026Q3 FY2026: net income +C$319K (probably a non-operating gain); current debt down to C$564K WeissBalance-sheet repair
7 May 2026Australian patent application accepted StockTitanIP in the trial jurisdiction
20 May 202650,001 DSUs to independent directors at C$0.15 StockwatchCash conservation
8 Jun 2026Australian notice of allowance announced StockTitanIP news
17 Jun 2026Q3 FY2026 results released Wealth AwesomeDisclosure
26 Jun 2026Shares rise 6.25% to C$0.17 on autism research interest Wealth AwesomeSentiment
2026Fragile X mouse data: behavioural and cognitive deficits reversed StockAnalysis feedSecond rare-disease efficacy signal
16 Jul 2026Placement of up to C$3.0M at C$0.15 announced NewsfilePhase I deposit financing
31 Jul 2026FY2026 year-end; prior DSUs vest Newsfile company pageAnnual audit cycle (audited FY2026 statements due by late Nov 2026)
19 Aug 2026Placement update Newsfile (referenced 29 Sep 2026)Closing slips
9 Sep 2026TSXV extends placement deadline to 14 Sep 2026 BiopharmaWatchWeak demand signal
29 Sep 2026Placement closes at C$1.60M (53% of maximum) NewsfileFunds Phase I deposit only

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Income Statement

3 charts
Income Statement (FY2021–FY2025): Pre-tax income rose from CAD -3 Mn in FY2021 to CAD -1.6 Mn in FY2025.
Alphanco Venture Corp — Income Statement (FY2021–FY2025)
Series (CAD Mn)FY2021FY2022FY2023FY2024FY2025
Pre-tax income-3-2.6-2.3-1.7-1.6
Net income-3-2.6-2.3-1.7-1.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Newsfile Corp. / BioSpace, "Alphanco Venture Corp. Changes Name to Marvel Biosciences Corp. and Completes Acquisition of Marvel Biotechnology Inc.", 8 Jul 2021. (newsfilecorp.com)
  2. Newswire.ca, TSX Venture Exchange Stock Maintenance Bulletins, 26 Feb 2019. (newswire.ca)
  3. Newsfile, "Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million", 29 Sep 2026. (newsfilecorp.com)
  4. Webull / Newsfile, "Marvel Biosciences Announces Private Placement for up to $3.0 Million", 16 Jul 2026. (webull.com)
  5. BiopharmaWatch, placement extension, 9 Sep 2026. (biopharmawatch.com)
  6. Stockwatch, DSU grant, 20 May 2026. (stockwatch.com)
  7. Stockwatch, Alberta Innovates funding, 30 Mar 2026. (stockwatch.com)
  8. Newsfile / Nasdaq, NRC IRAP pediatric formulation funding, 18 Feb 2026. (nasdaq.com)
  9. GlobeNewswire, "Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders", 16 Apr 2026. (globenewswire.com)
  10. Investing News Network, "Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204", 2026. (investingnews.com)
  11. BioSpace, "Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures", Apr 2026. (biospace.com)
  12. StockTitan, Australian patent notice of allowance, Jun 2026. (stocktitan.net)
  13. Newsfile, Marvel Biosciences company news page. (newsfilecorp.com)
  14. Newsfile, CFO change, 1 Feb 2022. (newsfilecorp.com)
  15. Newsfile, AGM proxy tabulation results (2022). (newsfilecorp.com)
  16. Newsfile, Director appointment (Pedram), 24 Nov 2022. (newsfilecorp.com)
  17. Weiss Ratings, MBCOF income statement, balance sheet and cash flow (quarterly and TTM). (weissratings.com)
  18. TipRanks, MRVL annual income statement. (tipranks.com)
  19. roic.ai, MRVL.V. (roic.ai)
  20. Simply Wall St, TSXV:MRVL and OTC:MBCO.F management pages. (simplywall.st)
  21. Yahoo Finance, MBCOF quote and profile. (ca.finance.yahoo.com)
  22. moomoo, MRVL company profile. (moomooapp.com)
  23. Investing.com, Marvel Biosciences. (uk.investing.com)
  24. Seeking Alpha, MBCOF balance sheet. (seekingalpha.com)
  25. Crux Investor, Marvel Biosciences interview. (cruxinvestor.com)
  26. moreblossom, Marvel Biosciences stakeholder tracker. (moreblossom.com)
  27. Wealth Awesome, MRVL coverage, Jun 2026. (wealthawesome.com)
  28. Pluang, placement closing summary, 29 Sep 2026. (pluang.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.